Last reviewed · How we verify
LJPC-501
LJPC-501 is a recombinant human C5a receptor antagonist that blocks complement activation and reduces inflammatory cell recruitment.
LJPC-501 is a recombinant human C5a receptor antagonist that blocks complement activation and reduces inflammatory cell recruitment. Used for Acute respiratory distress syndrome (ARDS), Sepsis-related conditions.
At a glance
| Generic name | LJPC-501 |
|---|---|
| Also known as | angiotensin II |
| Sponsor | La Jolla Pharmaceutical Company |
| Drug class | Complement C5a receptor antagonist |
| Target | C5a receptor (C5aR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | Phase 3 |
Mechanism of action
LJPC-501 binds to the C5a receptor on immune cells, preventing the potent anaphylatoxin C5a from triggering excessive complement-mediated inflammation. By blocking this pathway, the drug reduces neutrophil activation and recruitment to sites of inflammation, thereby dampening the inflammatory cascade implicated in various acute and chronic conditions.
Approved indications
- Acute respiratory distress syndrome (ARDS)
- Sepsis-related conditions
Common side effects
- Infusion-related reactions
- Headache
- Nausea
Key clinical trials
- Prognostic Interest of Vasorin in Septic Shock (NA)
- Angiotensin II in Liver Transplantation (PHASE2, PHASE3)
- Dysfunctional Renin-Angiotensin System in Septic Shock (PHASE4)
- Early Angiotensin II in the Emergency Department (PHASE4)
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. (PHASE2)
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria (PHASE2)
- Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LJPC-501 CI brief — competitive landscape report
- LJPC-501 updates RSS · CI watch RSS
- La Jolla Pharmaceutical Company portfolio CI